GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hemagen Diagnostics HMGN · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2012

Revenue

$4.0m

FY2012FY2012

Net income

−$907,315

FY2012FY2012

Free cash flow

−$449,724

FY2012FY2012

Shareholders' equity

−$3.6m

FY2012FY2012

Income statement

Fiscal years

FY2012
Revenue$4.0m
Gross profit$1.6m
Research and development$44,647
Operating income−$437,914
Net income−$907,315
Diluted earnings per share-0.06

Balance sheet

At each fiscal year end

FY2012
Total assets$2.4m
Cash and short-term investments$66,287
Total liabilities$6.0m
Debt$5.0m
Shareholders' equity−$3.6m
Shares outstanding15m

Cash flow

Fiscal years

FY2012
Cash from operations−$358,687
Capital spending−$91,037
Free cash flow−$449,724

Latest quarters

By quarter end

Sept 2012Jun 2012Mar 2012Dec 2011Sept 2011Jun 2011Mar 2011Dec 2010
Revenue$875,912$947,807$1.1m$1.1m$1.1m$1.4m$1.2m$1.4m
Gross profit$402,129$453,455$350,530$407,331$467,889$667,570$315,527$509,811
Operating income−$43,705−$12,303−$127,199−$254,707−$169,453$60,207−$272,012−$91,458
Net income−$162,983−$132,132−$243,642−$368,559−$281,879−$48,084−$366,333−$184,179
Diluted earnings per share-0.01-0.01-0.02-0.02-0.02-0.00-0.02-0.01
Total assets$2.4m$2.5m$2.6m$2.6m$2.9m$3.2m$3.1m$3.2m
Cash and short-term investments$66,287$107,308$86,877$18,863$213,611$209,933$299,408$256,672
Debt$976,868$976,868$894,438$719,426$4.7m$4.7m$4.6m$4.4m
Shareholders' equity−$3.6m−$3.4m−$3.2m−$3.0m−$2.7m−$2.3m−$2.3m−$2.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-9.3%-2.1%-8.2%
Operating income7.9%22.5%-4.2%
Net income3.9%1.3%-6.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin38.9%40.4%41.2%35.8%
Operating margin-9.9%-5.2%-3.5%-4.5%
Net margin-19.5%-13.9%-10.3%-15.8%

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return100%0%0%0%-93%107%1217%95%2612%2172%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.